Apogee Therapeutics Form 4: William Jones Jr. Granted Options

Rhea-AI Filing Summary

Apogee Therapeutics (APGE) filed a Form 4 disclosing that director William A. Jones Jr. received a grant of 14,461 non-qualified stock options on 17 June 2025. The options carry an exercise price of $41.66 and expire on 17 June 2035. According to the filing, the award vests 100 % on the first anniversary of the grant date, contingent upon Mr. Jones’ continued service. The transaction increases his derivative holdings to 14,461 options; there was no concurrent acquisition or disposition of common shares. Because this is a routine director equity grant with no immediate cash outlay, it does not directly affect Apogee’s share count, earnings or cash flow, but it modestly aligns the director’s incentives with future shareholder value.

Insights

Corporate Governance Expert

TL;DR - Standard director option grant; immaterial impact.

The reported transaction is a routine, single-person option award typical for newly appointed or continuing independent directors. The one-year cliff vesting is standard and supports alignment without encouraging short-termism. There is no dilution beyond the existing equity incentive plan burn rate, and the aggregate notional value (~$0.6 m using Black-Scholes assumptions) is immaterial to Apogee’s capitalization. Consequently, governance risk or shareholder dilution concerns are negligible.

Portfolio Manager

TL;DR - Neutral for valuation; signals director confidence.

While the grant itself does not alter fundamentals, the $41.66 strike sets a performance hurdle above current trading (level not disclosed here). The award can be read as a modest vote of confidence but provides no new information on operations, pipeline, or financial outlook. I view the filing as non-impactful for near-term valuation or trading strategy.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider JONES WILLIAM A JR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	14,461	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 14,461 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JONES WILLIAM A JR

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$41.66	06/17/2025		A		14,461		(1)	06/17/2035	Common Stock	14,461	$0.00	14,461	D

Explanation of Responses:

1. This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

	/s/ Matthew Batters, as attorney-in-fact for William Jones	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Apogee Therapeutics (APGE) report in its latest Form 4?

APGE disclosed a grant of 14,461 stock options to director William A. Jones Jr. on 17 June 2025.

What is the exercise price of the new APGE stock options?

The options have an exercise price of $41.66 per share.

When do the options granted to William Jones Jr. vest?

They vest 100 % on the first anniversary of the 17 June 2025 grant date, subject to continued service.

How many APGE shares are underlying the granted options?

The options give the right to acquire 14,461 shares of Apogee common stock.

Does this Form 4 affect Apogee Therapeutics’ share count?

No immediate change; dilution occurs only if the options are exercised after vesting.